Phospholipase Cβ2 Promotes Vascular Endothelial Growth Factor Induced Vascular Permeability
BackgroundRegulation of vascular permeability (VP) is critical to maintaining tissue metabolic homeostasis. Vascular endothelial growth factor (VEGF) is a key stimulus of VP in acute and chronic diseases including ischemia reperfusion injury, sepsis and cancer. Identification of novel regulators of VP would allow for the development of effective targeted therapeutics for patients with unmet medical need. MethodsIn vitro and in vivo models of VEGFA-induced vascular permeability, pathological permeability, quantitation of intracellular calcium release and cell entry, and PIP2 levels were evaluated with and without modulation of PLC{beta}2. ResultsGlobal knock-out of PLC{beta}2 in mice resulted in blockade of VEGFA-induced vascular permeability in vivo and trans-endothelial permeability in primary lung endothelial cells. Further work in an immortalized human microvascular cell line modulated with stable knock-down of PLC{beta}2 recapitulated the observations in the mouse model and primary cell assays. Additionally, loss of PLC{beta}2 limited both intracellular release and extracellular entry of calcium following VEGF stimulation as well as reduced basal and VEGFA-stimulated levels of PIP2 compared to control cells. Finally, loss of PLC{beta}2 in both a hyperoxia induced lung permeability model and a cardiac ischemia:reperfusion model resulted in improved animal outcomes when compared to WT controls. ConclusionsThe results implicate PLC{beta}2 as a key positive regulator of VEGF-induced VP through regulation of both calcium flux and PIP2 levels at the cellular level. Targeting of PLC{beta}2 in a therapeutic setting may provide a novel approach to regulating vascular permeability in patients. Graphic Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY HighlightsO_LIPLC{beta}2 promotes VEGFA induced vascular permeability. C_LIO_LILoss of PLC{beta}2 prevents VEGFA vascular permeability via repression of cellular calcium flux and membrane PIP2 levels. C_LIO_LILoss of PLC{beta}2 reduces vascular permeability and improves outcomes in a hyperoxic lung damage model and a cardiac ischemia:reperfusion model in vivo. C_LIO_LITargeting PLC{beta}2 inhibition may lead to a novel therapeutic for diseases such as stroke and myocardial infarction. C_LI